|
News Shire’s VENVANSE® (lisdexamfetamine dimesylate) Marketing Application accepted for review in Europe
Shire plc, the global specialty biopharmaceutical company, announced the acceptance for review of their once-daily ADHD medicinal product VENVANSE® (lisdexamfetamine dimesylate) by the Medicines Healthcare products Regulatory Agency (MHRA), UK. |
|
News FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults
The U.S. Food and Drug Administration (FDA) is updating its communication on the ongoing cardiovascular safety review of medications used for treating Attention-Deficit/Hyperactivity Disorder (ADHD), many of which are known to increase heart rate and blood pressure. |
|
News EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD
Shire plc the global specialty biopharmaceutical company, presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). |
|
News First Results of European Survey Show Significant Impact Of ADHD At School And Home, Yet Parents Wait Over Two Years for An ADHD Diagnosis
Shire plc, the global specialty biopharmaceutical company, announced the results of a new European survey that found children with ADHD have statistically significant impairments in all aspects of life investigated vs. children without ADHD. |
|
News Watson Launches Generic Concerta
Watson Pharmaceuticals confirmed that its subsidiary, Watson Laboratories, Inc., has launched an authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets) as part of an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). |
|
News FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
Shire plc the global specialty biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. |
|
News Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters into Agreement for CONCERTA Authorized Generic
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA® (methylphenidate HCl extended-release tablets). |
|
News Watson Signs Exclusive Agreement to Distribute Authorized Generic Concerta
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta(R) (methylphenidate hydrochloride extended-release tablets). |
|
News Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
Shire plc, the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone. |
|
News FDA Approves Kapvay
The U.S. Food and Drug Administration approval of the non-stimulant medication Kapvay (clonidine hydrochloride) extended-release tablets, an extended-release oral formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6-17 years. |
|
Article ADHD (Attention Deficit Hyperactivity Disorder)
Is it hard for your child to sit still? |
|
News Study Evaluated Vyvanse (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Data Showed Vyvanse Significantly Improved ADHD Symptoms of Inattention, Hyperactivity and Impulsivity in Adolescents Aged 13 to 17 |
|
News New Data Analyses of CONCERTA Efficacy on ADHD in the Classroom
New Orleans, LA (May 25, 2010) – Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),[1] according to the National Institute of Mental Health (NIMH). |
|
News FDA Approves Labeling Change for Vyvanse® (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, |
